News

FDA approves Portrazza to treat advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. READ MORE

Read More

FDA approves Darzalex for patients with previously treated multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of […]

Read More